Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus NYSERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus NYSERT.
KERYDIN vs NYSERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
10 mg orally once daily at bedtime, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Category C
Category C
Antifungal
Antifungal